Cell Signaling Technology

Product Pathways - Lymphocyte Signaling

Hck Antibody #4352

Applications Reactivity Sensitivity MW (kDa) Source
W H M Mk Endogenous 61 Rabbit

Applications Key:  W=Western Blotting
Reactivity Key:  H=Human  M=Mouse  Mk=Monkey
Species cross-reactivity is determined by western blot. Species enclosed in parentheses are predicted to react based on 100% sequence homology.

Protocols

Specificity / Sensitivity

Hck Antibody detects endogenous levels of total Hck protein. This antibody does not cross-react with family members Src, Lyn and Fyn.

Source / Purification

Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to amino-terminal residues of human Hck. Antibodies are purified by protein A and peptide affinity chromatography

Western Blotting

Western Blotting

Western blot analysis of cell extracts from various cell lines, using Hck Antibody.

Background

Hck (hemopoietic cell kinase) is a protein tyrosine kinase of the Src family prominently expressed in the lymphoid and myeloid lineages of hemopoiesis (1). It participates in transducing a variety of extracellular signals, which ultimately affect cellular processes including proliferation, differentiation and migration.The well-defined modular structure of Hck comprises a relatively divergent, NH2-terminal "unique" domain, which is subject to post-translational lipid modifications thereby targeting Hck to the plasma membrane. Src homology 3 (SH3) and 2 (SH2) domains, and a tyrosine kinase catalytic domain follow the "unique" domain. The catalytic activity of Hck is regulated, both positively and negatively, by tyrosine phosphorylation of highly conserved tyrosine (Y) residues. Phosphorylation of a single conserved Tyr499 residue in the COOH terminus of Hck by the protein kinase Csk renders Hck inactive as a result of an intramolecular interaction between the phosphorylated tyrosine (pY) residue and its own SH2 domain. Disruption of this interaction, either as a result of dephosphorylation, or substitution of the COOH-terminal regulatory Y residue with phenylalanine (F; e.g., HckY499F), or COOH-terminal truncation mutations as observed in the virally transduced v-Src oncoprotein, results in constitutive activation of Hck. In contrast to phosphorylation of the COOH-terminal regulatory tyrosine residue, autophosphorylation of a tyrosine residue (Tyr388) within the kinase domain of Hck acts to positively regulate its catalytic activity. Thus, activation of Hck requires both disruption of the COOH-terminal regulatory tyrosine-SH2 domain interaction and autophosphorylation of the regulatory tyrosine residue within the kinase domain ( 2, 3). The dysfunction or dysregulation of Hck may contribute to the pathogenesis of some human leukemias (4).

  1. Quintrell, N. et al. (1987) Mol. Cell. Biol. 7, 2267-2275.
  2. Ziegler, C.A. et al. (1989) Mol. Cell. Biol. 9, 2724-2727.
  3. Kefalas, P. et al. (1995) Int. J. Biochem. Cell. Biol. 27, 551-563.
  4. Hu, Y. et al. (2004) Nat. Genet. 36, 453-461.

Application References

Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!

Companion Products

For Research Use Only. Not For Use In Diagnostic Procedures.

Products